Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
Holding a dose indefinitely: is there a documented downside?
Stepping down deliberately: the withdrawal trials show that stopping is followed by regain. The step-down literature is thinner. The conservative assumption is that stepping down is followed by some regain, with the magnitude unknown.
I read post #17 twice before replying, because I had assumed the opposite.
Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.
How the published trials escalated: they used specific step sizes and intervals. The STEP programme used a particular cadence; the SURPASS and SURMOUNT programmes used slightly different ones. Reading them side by side shows the variation is real but small.
Read the full topic (33 posts)
This topic was referenced in
- Coming back to: Where the four-week escalation interval comes from, and what it is notPractice › Dosing & titration · 48 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: The arithmetic of an intermediate dose between two label steps
Revisiting: The arithmetic of an intermediate dose between two label steps Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
|
+41 | 45 | 808 | 2mo |
|
[2026 update] Dose numbers across compounds are not on the same scale
On the subject in the title: Dose numbers across compounds are not on the same scale Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking…
|
+14 | 18 | 1.2k | 13mo |
|
Where the four-week escalation interval comes from, and what it is not
On the subject in the title: Where the four-week escalation interval comes from, and what it is not Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I…
|
+56 | 60 | 21k | 2y |
|
Coming back to: Where the four-week escalation interval comes from, and what it is not
Posting this under the heading it deserves: Where the four-week escalation interval comes from, and what it is not Everything below is what sits behind that. I have read the maintained page on this and I…
|
+44 | 48 | 11k | 1d |
|
Why "dose equivalence" between different incretin analogues is a weak concept
Why "dose equivalence" between different incretin analogues is a weak concept I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on this…
|
+124 | 133 | 11k | 5mo |
Related topics — sharing the tags dose reduction, missed dose, semaglutide
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] Dose numbers across compounds are not on the same scale
On the subject in the title: Dose numbers across compounds are not on the same scale Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking…
|
+14 | 18 | 1.2k | 13mo |
|
Reaching a dose and staying there for a year: a longitudinal note
Reaching a dose and staying there for a year: a longitudinal note Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still have a…
|
2 | 763 | 15mo | |
|
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a certificate in front…
|
+22 | 26 | 1.8k | 9mo |
|
How the published trials escalated, tabulated side by side — does this still hold?
Asking directly, because I could not find a straight answer: How the published trials escalated, tabulated side by side — does this still hold? A question about technique rather than about dose. I have been…
|
2 | 8.9k | 9mo | |
|
Drawing from a pen cartridge with a syringe: how the risk profile changes
Posting this under the heading it deserves: Drawing from a pen cartridge with a syringe: how the risk profile changes Everything below is what sits behind that. I have read the maintained page on this and I…
|
2 | 159 | 19mo |